On the Pathogenesis and Neuroprotective Treatment of Parkinson Disease: What have we Learned from the Genetic Forms of this Disease?

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|15|23|2305-2320

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.15, Iss.23, 2008-10, pp. : 2305-2320

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neurotrophic Factors in Parkinson’s Disease: What Have we Learned from Pre-Clinical and Clinical Studies?

Current Medicinal Chemistry, Vol. 25, Iss. 31, 2018-09 ,pp. : 3682-3702

Bentham Science Publishers

Access to resources Recommend Favorite

Myc - What We have Learned from Flies

Current Drug Targets, Vol. 10, Iss. 7, 2009-07 ,pp. : 590-601

Bentham Science Publishers

Access to resources Recommend Favorite

Genetic Insights into Sepsis: What have we Learned and How will it Help?

Current Pharmaceutical Design, Vol. 14, Iss. 19, 2008-07 ,pp. : 1900-1911

Bentham Science Publishers

Access to resources Recommend Favorite

Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?

By Urban Thomas J Goldstein David B Watkins Paul B

Pharmacogenomics, Vol. 13, Iss. 7, 2012-05 ,pp. : 735-738

Future Medicine

Access to resources Recommend Favorite

Monoamine Oxidase Inhibitors Extracted from Tobacco Smoke as Neuroprotective Factors for Potential Treatment of Parkinson’s Disease

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 14, Iss. 6, 2015-01 ,pp. : 777-785

Bentham Science Publishers

Access to resources Recommend Favorite